Shares of Clovis Oncology Inc. (CLVS) are up an impressive 48% year-to-date while the iShares Nasdaq Biotechnology ETF (IBB) index has gained only 19% during the same period.
Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe, and other international markets.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com